ARJUNA Therapeutics Awarded Prize at the 2024 MATWIN Congress

A CORUÑA, Spain - May 23, 2024 - PRLog -- ARJUNA Therapeutics is pleased to announce the award of a prize from the
MATWIN International Board at the 2024 MATWIN Congress in Bordeaux, France.
The jury comprises senior oncology R+D and Business Development personnel from
large pharmaceutical companies based in the USA and Europe.
Dr Ross Breckenridge PhD FRCP, CEO said; "We are delighted that the committee
chose ARJUNA as one of the top companies presenting. This award is validation of
our unique programme of developing Therapeutic Molecular Clusters for treatment of
incurable cancers. The committee members have also provided us with a large
amount of valuable, actionable advice for clinical development of our lead asset,
Ag5. This will aid our progress into the clinic at the end of 2025".

ARJUNA Therapeutics is a preclinical stage Europe-based biotech developing a
novel platform of small molecules made by quantum chemistry. Our first molecule,
Ag5, targets cancer mitochondria via a unique catalytic mechanism and will initially
be tested in metastatic non-small-cell lung cancer and glioblastoma.

For more information, please visit: www.arjunatherapeutics.com